Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:53 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: | NSE:

Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹0.96Overvalued by 83.59%vs CMP ₹5.85

P/E (15.0) × ROE (1.5%) × BV (₹5.16) × DY (2.00%)

Defaults: P/E=15

₹2.87Overvalued by 50.94%vs CMP ₹5.85
MoS: -103.8% (Negative)Confidence: 50/100 (Moderate)Models: 2 Under, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹0.8925%Over (-84.8%)
Graham NumberEarnings₹3.0523%Over (-47.9%)
Earnings PowerEarnings₹0.0515%Over (-99.1%)
Net Asset ValueAssets₹5.1410%Over (-12.1%)
Earnings YieldEarnings₹0.8010%Over (-86.3%)
ROCE CapitalReturns₹7.9210%Under (+35.4%)
Revenue MultipleRevenue₹7.598%Under (+29.7%)
Consensus (7 models)₹2.87100%Overvalued
Key Drivers: ROE 1.5% is below cost of equity. | Wide model spread (₹0–₹8) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -7.4% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

44
Vaishali Pharma Ltd scores 44/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health53/100 · Moderate
ROCE 4.9% WeakROE 1.5% WeakD/E 0.71 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding stable No changePromoter increased by 5.29% Positive
Earnings Quality30/100 · Weak
OPM contracting (11% → 2%) DecliningWorking capital: 231 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +15% YoY GrowingProfit (4Q): -223% YoY Declining
Industry Rank30/100 · Weak
ROCE 4.9% vs industry 11.7% Below peersROE 1.5% vs industry 22.9% Below peers3Y sales CAGR: 9% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:53 am

Market Cap 76.3 Cr.
Current Price 5.85
Intrinsic Value₹2.87
High / Low 15.2/4.75
Stock P/E
Book Value 5.16
Dividend Yield0.00 %
ROCE4.93 %
ROE1.52 %
Face Value 2.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vaishali Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Gujarat Metallic Coal & Coke Ltd 5.94 Cr. 30.0 / 77.60.00 %0.37 %2.00 % 100
Gensol Engineering Ltd 73.7 Cr. 19.2 166/18.60.72 1550.00 %14.3 %22.4 % 10.0
Fusion Micro Finance Ltd 2,335 Cr. 145 212/124 1180.00 %2.96 %54.5 % 10.0
Five X Tradecom Ltd 0.99 Cr. 0.48/ 9.350.00 %0.00 %0.00 % 10.0
East West Holdings Ltd 29.8 Cr. 2.34 7.43/1.85 4.930.00 %6.98 %0.86 % 2.00
Industry Average7,439.67 Cr186.66153.03219.100.31%11.73%22.92%9.00

All Competitor Stocks of Vaishali Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 20.0926.2413.4212.5727.9032.4018.0820.7927.9132.2523.7533.4524.65
Expenses 16.5325.4611.119.9224.9539.1915.7318.3726.5538.2922.3832.0623.09
Operating Profit 3.560.782.312.652.95-6.792.352.421.36-6.041.371.391.56
OPM % 17.72%2.97%17.21%21.08%10.57%-20.96%13.00%11.64%4.87%-18.73%5.77%4.16%6.33%
Other Income 0.530.530.360.300.470.910.420.711.071.000.840.840.89
Interest 0.420.540.430.470.430.400.380.380.380.440.330.400.51
Depreciation 0.120.150.120.120.120.140.120.120.120.120.140.170.13
Profit before tax 3.550.622.122.362.87-6.422.272.631.93-5.601.741.661.81
Tax % 25.07%29.03%25.00%27.97%26.13%-26.95%25.11%25.10%24.87%-23.39%26.44%28.31%28.18%
Net Profit 2.660.441.591.702.11-4.681.701.971.44-4.291.281.181.30
EPS in Rs 0.250.040.150.160.20-0.440.160.180.13-0.400.120.090.10

Last Updated: March 3, 2026, 1:56 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 9:10 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1219567646875605476708699114
Expenses 1189566606573595169608598116
Operating Profit 2-01332137921-2
OPM % 2%-0%1%5%4%3%2%5%9%13%2%1%-2%
Other Income 1431222222234
Interest 3333333322222
Depreciation 0000000000101
Profit before tax 10-0111016911-0
Tax % 50%-7%300%32%41%37%62%26%30%25%23%34%
Net Profit 00-0111014711-1
EPS in Rs 0.380.20-0.040.150.080.070.000.100.380.630.070.08-0.09
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%0.00%-100.00%300.00%75.00%-85.71%0.00%
Change in YoY Net Profit Growth (%)0.00%0.00%-100.00%400.00%-225.00%-160.71%85.71%

Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:0%
5 Years:11%
3 Years:9%
TTM:15%
Compounded Profit Growth
10 Years:18%
5 Years:94%
3 Years:-41%
TTM:-52%
Stock Price CAGR
10 Years:%
5 Years:24%
3 Years:8%
1 Year:-35%
Return on Equity
10 Years:7%
5 Years:8%
3 Years:6%
Last Year:2%

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: December 10, 2025, 3:37 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.500.500.5037711111111112626
Reserves 3331141511121630323941
Borrowings 19252123181717182115131216
Other Liabilities 32172518253028463424243339
Total Liabilities 5346494564696686827980110122
Fixed Assets 0211111112222
CWIP 0000000001100
Investments 0000000000005
Other Assets 5344484362676484807677107114
Total Assets 5346494564696686827980110122

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -7-450-9432111-18
Cash from Investing Activity + -02311-0-0-0-101-0
Cash from Financing Activity + 62-8-18-4-3-20-2-118
Net Cash Flow -100-000001-010
Free Cash Flow -8-550-10432011-18
CFO/OP -276%1,252%842%16%-326%212%433%78%31%28%185%-3,104%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-17.00-25.00-20.00-20.00-15.00-15.00-16.00-15.00-14.00-6.00-11.00-11.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 116133221214240240286453282281209172
Inventory Days 261320711565420220
Days Payable 996614510013613016932116312095116
Cash Conversion Cycle 43809612111511512313712218111677
Working Capital Days 599825149798124146111208169231
ROCE %19%14%13%16%13%10%7%10%19%22%6%5%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 26.74%26.74%26.62%26.62%26.32%26.32%26.32%26.32%26.32%26.32%26.32%31.61%
FIIs 0.57%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 72.69%73.26%73.38%73.38%73.68%73.68%73.67%73.68%73.68%73.68%73.68%68.39%
No. of Shareholders 9,3769,5739,9839,1819,3909,47918,98327,54628,87428,68227,75227,148

Shareholding Pattern Chart

No. of Shareholders

Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.060.686.263.820.99
Diluted EPS (Rs.) 0.060.645.913.820.99
Cash EPS (Rs.) 0.091.146.744.251.40
Book Value[Excl.RevalReserv]/Share (Rs.) 4.9833.4131.2624.9921.26
Book Value[Incl.RevalReserv]/Share (Rs.) 4.9833.4131.2624.9921.26
Revenue From Operations / Share (Rs.) 7.5980.4966.0571.8950.99
PBDIT / Share (Rs.) 0.252.9610.778.204.21
PBIT / Share (Rs.) 0.212.4810.297.763.81
PBT / Share (Rs.) 0.090.868.395.431.33
Net Profit / Share (Rs.) 0.060.676.263.810.99
PBDIT Margin (%) 3.323.6716.3011.398.26
PBIT Margin (%) 2.833.0815.5810.797.46
PBT Margin (%) 1.231.0712.697.552.61
Net Profit Margin (%) 0.820.839.475.301.94
Return on Networth / Equity (%) 1.252.0020.0215.264.66
Return on Capital Employeed (%) 4.025.6823.1727.5714.94
Return On Assets (%) 0.740.898.364.921.21
Long Term Debt / Equity (X) 0.060.100.150.110.18
Total Debt / Equity (X) 0.170.350.410.780.71
Asset Turnover Ratio (%) 1.041.090.860.900.70
Current Ratio (X) 2.612.252.271.471.37
Quick Ratio (X) 2.492.242.171.461.36
Inventory Turnover Ratio (X) 38.160.000.000.000.00
Interest Coverage Ratio (X) 2.081.835.663.521.70
Interest Coverage Ratio (Post Tax) (X) 1.521.414.292.641.40
Enterprise Value (Cr.) 173.94161.15166.5589.1749.85
EV / Net Operating Revenue (X) 1.761.872.391.180.92
EV / EBITDA (X) 52.7850.8214.6610.3211.22
MarketCap / Net Operating Revenue (X) 1.661.742.210.920.63
Price / BV (X) 2.534.194.672.651.53
Price / Net Operating Revenue (X) 1.661.742.210.920.63
EarningsYield 0.000.000.040.050.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Vaishali Pharma Ltd. is a Public Limited Listed company incorporated on 25/03/2008 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L52310MH2008PLC181632 and registration number is 181632. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 99.03 Cr. and Equity Capital is Rs. 26.09 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra 400092Contact not found
Management
NamePosition Held
Mr. Atul Arvind VasaniChairman & Managing Director
Mr. Dewansh Ajay VasaniExecutive Director & CFO
Mrs. Jagruti Atul VasaniWhole Time Director
Mr. Manish Bhagwandas VedInd. Non-Executive Director
Mr. Pratik Vikram JakheliaInd. Non-Executive Director
Mr. Bhaveshkumar UpadhyayNon Exe.Non Ind.Director

FAQ

What is the intrinsic value of Vaishali Pharma Ltd and is it undervalued?

As of 14 April 2026, Vaishali Pharma Ltd's intrinsic value is ₹2.87, which is 50.94% lower than the current market price of ₹5.85, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (1.52 %), book value (₹5.16), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Vaishali Pharma Ltd?

Vaishali Pharma Ltd is trading at ₹5.85 as of 14 April 2026, with a FY2026-2027 high of ₹15.2 and low of ₹4.75. The stock is currently near its 52-week low. Market cap stands at ₹76.3 Cr..

How does Vaishali Pharma Ltd's P/E ratio compare to its industry?

Vaishali Pharma Ltd has a P/E ratio of , which is below the industry average of 153.03. This is broadly in line with or below the industry average.

Is Vaishali Pharma Ltd financially healthy?

Key indicators for Vaishali Pharma Ltd: ROCE of 4.93 % is on the lower side compared to the industry average of 11.73%; ROE of 1.52 % is below ideal levels (industry average: 22.92%). Dividend yield is 0.00 %.

Is Vaishali Pharma Ltd profitable and how is the profit trend?

Vaishali Pharma Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹99 Cr. Compared to ₹4 Cr in Mar 2022, the net profit shows a declining trend.

Does Vaishali Pharma Ltd pay dividends?

Vaishali Pharma Ltd has a dividend yield of 0.00 % at the current price of ₹5.85. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vaishali Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports